|
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 0.50 | ACUITE C | Assigned | - |
Bank Loan Ratings | 0.06 | ACUITE C | Downgraded | - |
Bank Loan Ratings | 39.50 | ACUITE D | Assigned | - |
Bank Loan Ratings | 25.19 | ACUITE D | Downgraded | - |
Bank Loan Ratings | 12.50 | - | ACUITE D | Downgraded |
Total Outstanding Quantum (Rs. Cr) | 77.75 | - | - |
Rating Rationale |
Acuité has downgraded its long-term rating to 'ACUITE D (read as ACUITE D) from ‘ACUITE B+’ (read as ACUITE B Plus) and downgraded its short term rating to 'ACUITE D' (Read as Acuite D) from ‘ACUITE A4’ (read as ACUITE A four) on the Rs.37.69 crore bank facilities of Lakshanya ventures private limited ( Erstwhile Encarta Pharma Private Limited) (LVPL). Acuité has downgraded its long-term rating to 'ACUITE C (read as ACUITE C) from ‘ACUITE B+’ (read as ACUITE B Plus) on the Rs.0.06 crore bank facilities of Lakshanya ventures private limited ( Erstwhile Encarta Pharma Private Limited) (LVPL). Acuité has assgined its long-term rating of 'ACUITE D (read as ACUITE D) on the Rs.39.50 crore bank facilities of Lakshanya ventures private limited ( Erstwhile Encarta Pharma Private Limited) (LVPL). Acuité has assgined its long-term rating of 'ACUITE C (read as ACUITE C) on the Rs.0.50 crore bank facilities of Lakshanya ventures private limited ( Erstwhile Encarta Pharma Private Limited) (LVPL). The rating is downgraded and assigned on account of recent delays in servicing of debt obligations by LVPL as confirmed by its respective banker. The rating continues to draw comfort from the experienced management and established track record of operations. |
About the Company |
LAKSHANYA VENTURES PRIVATE LIMITED , a Bangalore-based company was incorporated in 2001. Founded by Mr. Keerthan P, Mr. Ganesh R. Nayak and Mr. Girish M, the company is engaged in Cardiac & Endovascular Implants, ICU & OT Equipment’s and Ophthalmology products. The present directors of the company are Mr. Ganesh R. Nayak, Mr. Girissh Maheswarappa, Mr. Sharath S. Shetty and Mr. Pichamutal K. Premsagar.
|
Analytical Approach |
Acuité has considered the standalone business and financial risk profile of LVPL to arrive at the rating |
Key Rating Drivers
Strengths |
LVPL promoters possess over two decades of experience in the medical equipment trading business. The company benefits from established relationships with Hospital and Medical equipment OEMs. The product portfolio contains Cardiac & Endovascular Implants, ICU & OT Equipment and Ophthalmology products. Acuité believes that the market potential, healthy and reputed client base and diversified product portfolio of LVPL are expected to support in improvement of business risk profile over the medium term
|
Weaknesses |
LVPL has delayed in the repayment of the term loan facilities in the month of July 2023, June 2023, February 2023, January 2023 as per the banker confirmation.
|
Rating Sensitivities |
Regular servicing of debt obligations |
All Covenants |
None |
Liquidity Position: Poor |
The liquidity position of the company is marked poor on account of recent past instances of delays in servicing of debt obligation. |
Outlook: Not applicable |
|
Other Factors affecting Rating |
None |
Particulars | Unit | FY 23 (Provisional) | FY 22 (Actual) |
Operating Income | Rs. Cr. | 435.00 | 413.27 |
PAT | Rs. Cr. | 48.06 | 28.42 |
PAT Margin | (%) | 11.05 | 6.88 |
Total Debt/Tangible Net Worth | Times | 0.66 | 0.47 |
PBDIT/Interest | Times | 11.01 | 11.46 |
Status of non-cooperation with previous CRA (if applicable) |
ICRA vide its press release dated 20th March 2023, had rated the company to ICRA D; Issuer Not Cooperating. |
Any other information |
None |
Applicable Criteria |
• Default Recognition :- https://www.acuite.in/view-rating-criteria-52.htm • Trading Entitie: https://www.acuite.in/view-rating-criteria-61.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
Note on complexity levels of the rated instrument |
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in.
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Contacts |
|
|
About Acuité Ratings & Research |
Acuité Ratings & Research Limited | www.acuite.in |